Growth Metrics

Idexx Laboratories (IDXX) Current Deferred Revenue (2016 - 2026)

Idexx Laboratories has reported Current Deferred Revenue over the past 17 years, most recently at $35.3 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 4.33% year-over-year to $35.3 million; the TTM value through Dec 2025 reached $35.3 million, up 4.33%, while the annual FY2025 figure was $35.3 million, 4.33% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $35.3 million at Idexx Laboratories, down from $35.7 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $41.6 million in Q1 2021 and troughed at $33.8 million in Q4 2024.
  • A 5-year average of $38.3 million and a median of $38.0 million in 2022 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: increased 13.25% in 2021 and later decreased 9.13% in 2024.
  • Year by year, Current Deferred Revenue stood at $40.0 million in 2021, then decreased by 5.24% to $37.9 million in 2022, then decreased by 1.96% to $37.2 million in 2023, then decreased by 9.13% to $33.8 million in 2024, then rose by 4.33% to $35.3 million in 2025.
  • Business Quant data shows Current Deferred Revenue for IDXX at $35.3 million in Q4 2025, $35.7 million in Q3 2025, and $36.3 million in Q2 2025.